BTICs were derived from resected, newly diagnosed human malignant gliomas as previously described [12]. The sampling of tumor specimens and enrichment of BTICs was approved by the Ethics Committee of the University of Regensburg (No° 09/101), and all patients gave written informed consent. We used the following core set of lines for our experiments: BTIC-8, BTIC-11, BTIC-13, and BTIC-18 (Supplementary Table S1). BTICs were kept in DMEM low glucose medium (DMEM with 1 g/L of glucose; Sigma-Aldrich, #D6046) containing Epidermal Growth Factor (Miltenyi Biotec, #130-097-751, Bergisch Gladbach, Germany) and Fibroblast Growth Factor (Miltenyi Biotec, #130-093-842, Bergisch Gladbach, Germany) supplemented with 50 U (v/v) Penicillin, 0.05% (v/v) Streptomycin (#P4333), 2 mM (v/v) L-Glutamine (#G7513), 1% (v/v) MEM Vitamin Solution (#M6895), and 1% (v/v) non-essential amino acids (#M7145) (all Sigma-Aldrich, St. Louis, USA). For differentiation, growth factors were withdrawn, and cells were exposed to fetal calf serum (FCS) for at least two weeks. Cells were incubated at 37 °C, 5% CO2, 95% humidity in a standard cell culture incubator. All experiments were performed with mycoplasma-free cells.
Proliferation was assessed using the CyQUANT® Direct Cell Proliferation Assay (Thermo Scientific, #C35012, Waltham, MA, USA) according to the manufacturer’s protocol. The spheroid migration assays were performed as previously described [11]. To distinguish proliferation from migration effects, we used early time points, i.e., after 16 and 24 h, which preceded the cell doubling time (average doubling time of BTICs and TCs = 45.8 h).
BTICs und TCs were lentivirally transduced using U57 pHR SFFV GFP (BTIC-13 and TC-13) and pLenti-H1-(shRNA-Neg-control)-Rsv(RFP-Bsd) plasmids (BTIC-18 and TC-18). Lentivirally transduced BTICs were grown as spheroids in agarose-coated 96-well plates (10,000 cells/well) 48 h prior to implantation. OBSC were prepared according to Gogolla et al. [44] with individual modifications as described [12]. We implanted one spheroid per slice and used three technical replicates. Spheroid diameter ranged between 3 and 8 × 10−5 µm2 depending on initial cell size. Two days were sufficient to form cell spheroids that were transferrable by pipette. The lentiviral transduction did not affect proliferation or migration compared to non-transduced counterparts.
Metformin hydrochloride (Sigma-Aldrich #PHR1084, St. Louis, MI, USA) was dissolved in DMEM low glucose (5.5 mM) medium and used at indicated doses.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.